Novavax signed a definitive agreement to sell its manufacturing facility in Bohumil, Czech Republic to Novo Nordisk for $200 million.
- Agreement includes a transfer of assets, including a 150,000 sq. ft. facility
- Provides Novavax with $190m cash payment in 2024 and additional $10m in 2025
- Novavax expects the sale of the facility to result in annual operating cost reductions of ~$80m
- Deal expected to close by Dec. 30
- NOTE: In Nov.,
Novavax Slumps After Product Sales Outlook Miss Expectations
To view the source of this information, click
To contact the reporter on this story:
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.